IPO News | Ande Healthcare Plans Hong Kong Stock IPO, China Securities Regulatory Commission Requests Additional Explanation on Prices and Pricing Basis for Successive Capital Increases and Equity Transfers

Zhitong Finance App learned that on August 21, the China Securities Regulatory Commission issued the “Requirements for Supplementary Materials for Overseas Issuance and Listing Filing (August 17, 2026 - August 21, 2026)”. The International Division of the China Securities Regulatory Commission issued supplementary material requirements for a total of 3 companies. Among them, Amtech Healthcare was requested to provide additional explanations on matters such as the price and pricing basis of previous capital increases and equity transfers. According to reports, Ande Healthcare submitted a listing application to the main board of the Hong Kong Stock Exchange on May 15, 2026, with CITIC Construction Investment International as the sole sponsor.

The China Securities Regulatory Commission requested the company to further explain the following matters, and ask lawyers to conduct inspections and issue clear legal opinions:

1. Please explain: (1) The price and pricing basis for the company's previous capital increases and share transfers; whether there is an abnormal share price; whether there is an abnormal share price; whether there are any circumstances of failure to fulfill investment obligations, evasion of investment, and defects in funding methods; (2) Please issue a concluding opinion on whether the establishment of the company and the successive share changes are legal and compliant, and whether the company has entities prohibited from holding shares by laws and regulations; (3) Please explain the pricing basis for the company's share repurchases and the payment of taxes on the purchaser's fees.

2. Please verify the existing proxy holding situation in the company's history in accordance with the relevant requirements of the “Guidelines for the Use of Regulatory Rules - Overseas Issuance and Listing Class No. 2” and issue clear concluding opinions.

3. Please explain the specific circumstances and reasons for the withdrawal of the company's A-share listing guidance and filing in the early stages; please explain the company's internal decisions to pay dividends and the implementation of regulatory procedures such as tax payment during the reporting period, and explain the rationality of dividend payments based on factors such as the company's liabilities and cash flow, and the necessity of the company's current listing and financing.

According to the prospectus, Ande Medical is a leading provider of innovative medical consumables in China. The company adheres to an innovation-driven strategy to provide medical institutions with comprehensive and high-quality medical consumables solutions. According to Frost & Sullivan's data, according to the number of registration certificates for medical consumables products from the China National Drug Administration as of May 8, 2026, Ante Healthcare ranked second in China; according to the number of registration certificates as of May 8, 2026, the company is one of the most complete companies in vascular access products in the world; and in terms of 2025 revenue, the company's drug delivery products rank second in China.